Shares of Moderna dropped 2.78% to $113.03 at 14:10 EST on Thursday, following last session’s upward trend. NASDAQ Composite is jumping 2.3% to $13,033.27, following last session’s downward trend, This seems, up to now, an all-around positive trend trading session today.
Moderna’s last close was $116.26, 57.92% below its 52-week high of $178.50.
News about Moderna today
Moderna hires Amgen executive as chief commercial officer. According to today’s article on MarketWatch, "Shares of Moderna Inc. were down 0.2% in trading on Thursday after the company said it had hired an Amgen executive to run commercial operations as it rolls out the first doses of its COVID-19 vaccine, in the U.S. and elsewhere. "
Moderna’s sales growth is 1876.9% for the ongoing quarter and 19117.5% for the next. The company’s growth estimates for the ongoing quarter and the next is 18.9% and 660%, respectively.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna’s last day, last week, and last month’s average volatility was a positive 6.48%, a positive 0.36%, and a negative 1.35%, respectively.
Moderna’s last day, last week, and last month’s high and low average amplitude percentage was 6.03%, 8.65%, and 8.67%, respectively.
Moderna’s Stock Yearly Top and Bottom Value
Moderna’s stock is valued at $113.03 at 14:10 EST, way under its 52-week high of $178.50 and way higher than its 52-week low of $17.90.
Moderna’s Moving Average
Moderna’s value is way under its 50-day moving average of $129.70 and way higher than its 200-day moving average of $84.90.
Previous days news about Moderna
Moderna expects to deliver 100 million doses of its Covid-19 vaccine in the U.S. in Q1. According to MarketWatch on Monday, 4 January, "Shares of Moderna Inc. gained 0.4% in trading on Monday after the biotechnology company said it plans to produce 100 million doses of its COVID-19 vaccine in the first quarter for the U.S. market. ", "Globally, Moderna plans to deliver an estimated 500 to 600 million doses in 2021. "
Moderna expects to deliver 100 million vaccine doses in U.S. in first quarter. According to MarketWatch on Monday, 4 January, "Shares of Moderna Inc. gained 0.4% in trading on Monday after the biotechnology company said it plans to produce 100 million doses of its COVID-19 vaccine in the first quarter for the U.S. market. ", "That is the equivalent of 50 million vaccinations as the Moderna vaccine requires two doses. "
Moderna lifts vaccine output outlook 20% to at least 600 million. According to Bloomberg Quint on Monday, 4 January, "The U.S. has ordered 200 million doses of the vaccine, with options for buying 300 million more, and Moderna confirmed in the statement that it still expects to deliver all 200 million doses by the end of the second quarter.", "That puts Moderna roughly in line with its goal of delivering approximately 20 million doses to the U.S. last year."
Stocks making the biggest moves in the premarket: Micron Technology, first solar, Moderna & more. According to CNBC on Tuesday, 5 January, "Moderna (MRNA) – Moderna received approval for its Covid-19 vaccine from Israeli health regulators. "
Moderna covid vaccine wins EU backing in struggle to stem virus. According to Bloomberg Quint on Wednesday, 6 January, "The bloc has ordered 160 million doses of the Moderna vaccine, the company said last month.", "Germany expects to get more than 130 million doses of vaccine once the Moderna and BioNTech shots are shipped, he said — enough to inoculate 65 million people, or about three-quarters of the population."
Moderna shares gain at opening bell as vaccine wins EU medical regulator's OK. According to MarketWatch on Wednesday, 6 January, "Shares in Cambridge, Mass.-based biotech Moderna rose more than 3% in New York premarket trading on Wednesday.", "Also read: Moderna expects to deliver 100 million doses of its COVID-19 vaccine in the U.S. in Q1"
Covid-19 vaccine update – EMA recommends Moderna inc. vaccine.. According to FX Empire on Wednesday, 6 January, "While the distribution of the Moderna Inc. vaccine likely to commence in a matter of days, the EMA has yet to review the AstraZeneca vaccine.", "Today, the EMA’s human medicines Committee ("CHMP") recommended the COVID-19 Moderna Inc. vaccine for authorization."
Moderna gets EU approval; allergic reactions rare: virus update. According to Bloomberg Quint on Wednesday, 6 January, "About 5.2 million doses of Covid-19 vaccines from Pfizer Inc.-BioNTech SE and Moderna Inc. have been administered in the U.S. since mid-December, according to data compiled by Bloomberg News. ", "Operation Warp Speed has achieved that goal with vaccines from Pfizer Inc. and Moderna Inc. authorized for emergency use, along with antibody therapies available to treat Covid-19 cases."